Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Language | Translation |
---|---|
English | Malignant neoplasm of cervix uteri |
French | Tumeur maligne du col de l'utérus |
Level | Code | Title | |
---|---|---|---|
1 | II | Neoplasms | |
2 | C00-C97 | Malignant neoplasms | |
3 | C51-C58 | Malignant neoplasms of female genital organs | |
4 | C53 | Malignant neoplasm of cervix uteri |
Code | Title | |
---|---|---|
C53.0 | Malignant neoplasm: Endocervix | |
C53.1 | Malignant neoplasm: Exocervix | |
C53.8 | Malignant neoplasm: Overlapping lesion of cervix uteri | |
C53.9 | Malignant neoplasm: Cervix uteri, unspecified |
Active Ingredient | Description | |
---|---|---|
Bevacizumab |
Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth. |
|
Ifosfamide |
Ifosfamide is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes. The cytotoxic activity of ifosfamide (alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. This activity manifests itself by blocking the late S and early G2 phases of the cell cycle. |